Skip to content
Screener

Bicara Therapeutics BCAX Business Segments — Net loss

Similar metrics at other companies

Veradermics logo
MANEReportable Segment — Net loss
-$27.23M-120%
Zscaler logo
ZSReportable Segment — Net loss
-$13.88M-237%
Biohaven logo
BHVNReportable Segment — Net loss
-$130.53M+41.1%
YSS
YSSReportable Segment — Net loss
-$114.84M-879%
Vaxcyte, Inc. logo
PCVXReportable Segment — Net loss
-$320.62M-128%
Immunovant, Inc. logo
IMVTReportable Segment — Net loss
$147.86M+38.9%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.81B+217%
Enterprise value$1.49B+1,000%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033429
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Total other income4,0835,014
Net loss before income taxes(56,159)(36,774)
Income tax expense(52)(72)
Net loss$(56,211)$(36,846)
Net Loss per share, basic and diluted$(0.93)$(0.68)
Weighted-average number common shares outstanding, basic and diluted60,717,04154,456,515
Other comprehensive loss:
Unrealized loss on marketable securities, net of tax(486)

Item 1. Financial Statements (Unaudited)

FAQ

What is Bicara Therapeutics's business segments — net loss?
Bicara Therapeutics (BCAX) reported business segments — net loss of -$56.21M in Q1 2026.
How has Bicara Therapeutics's business segments — net loss changed year-over-year?
Bicara Therapeutics's business segments — net loss decreased by 52.6% year-over-year, from -$36.85M to -$56.21M.
What is the long-term trend for Bicara Therapeutics's business segments — net loss?
Over 2 years (2023 to 2025), Bicara Therapeutics's business segments — net loss has grown at a 62.9% compound annual growth rate (CAGR), from -$51.99M to -$137.95M.
What does business segments — net loss mean?
This metric represents the final bottom-line financial result after all operating expenses, taxes, and other non-operating items have been accounted for. For early-stage biopharmaceutical companies, this typically reflects the heavy investment in clinical trials and drug development relative to revenue generation.

Ask your AI about Bicara Therapeutics's business segments — net loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude